Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases
- PMID: 19536360
- DOI: 10.1358/mf.2009.31.3.1364241
Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases
Abstract
Citicoline is an essential precursor in the synthesis of phosphatidylcholine, a key cell membrane phospholipid, and is known to have neuroprotective effects in acute ischemic stroke. The aim of this study was to determine the efficacy and safety of oral citicoline in Korean patients with acute ischemic stroke. A drug surveillance study was carried out in 4,191 patients with a diagnosis of acute ischemic stroke. Oral citicoline (500-4000 mg/day) was administered within less than 24 h after acute ischemic stroke in 3,736 patients (early group) and later than 24 h after acute ischemic stroke in 455 patients (late group) for at least 6 weeks. For efficacy assessment, primary outcomes were patients' scores obtained with a short form of the National Institutes of Health Stroke Scale (s-NIHSS), a short form of the Barthel Index of activities of daily living (s-BI) and a modified Rankin Scale (mRS) at enrollment, after 6 weeks and at the end of therapy for those patients with extended treatment. All adverse reactions were monitored during the study period for safety assessment. All measured outcomes, including s-NIHSS, s-BI and mRS, were improved after 6 weeks of therapy (P < 0.05). Further improvement was observed in 125 patients who continued citicoline therapy for more than 12 weeks when compared with those who ended therapy at week 6. Improvements were more significant in the higher dose group (> or = 2000 mg/day) (P < 0.001). s-BI scores showed no differences between the early and late groups at the end of therapy. Citicoline safety was excellent; 37 side effects were observed in 31 patients (0.73%). The most frequent findings were nervous system-related symptoms (8 of 37, 21.62%), followed by gastrointestinal symptoms (5 of 37, 13.5%). Oral citicoline improved neurological, functional and global outcomes in patients with acute ischemic stroke without significant safety concerns.
Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
Similar articles
-
Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators.Ann Neurol. 2000 Nov;48(5):713-22. Ann Neurol. 2000. PMID: 11079534 Clinical Trial.
-
[Neuroprotection in acute ischemic stroke. Practicability of guidelines for treatment].Rev Neurol. 2001 May 1-15;32(9):818-21. Rev Neurol. 2001. PMID: 11424030 Spanish.
-
Citicoline for acute ischemic stroke in Mexican hospitals: a retrospective postmarketing analysis.Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):325-30. doi: 10.1358/mf.2010.32.5.1465004. Methods Find Exp Clin Pharmacol. 2010. PMID: 20664823
-
Citicoline: pharmacological and clinical review, 2006 update.Methods Find Exp Clin Pharmacol. 2006 Sep;28 Suppl B:1-56. Methods Find Exp Clin Pharmacol. 2006. PMID: 17171187 Review.
-
The effects of citicoline on acute ischemic stroke: a review.J Stroke Cerebrovasc Dis. 2014 Aug;23(7):1764-9. doi: 10.1016/j.jstrokecerebrovasdis.2014.01.020. Epub 2014 Apr 13. J Stroke Cerebrovasc Dis. 2014. PMID: 24739589 Review.
Cited by
-
Understanding the Pathophysiology of Ischemic Stroke: The Basis of Current Therapies and Opportunity for New Ones.Biomolecules. 2024 Mar 4;14(3):305. doi: 10.3390/biom14030305. Biomolecules. 2024. PMID: 38540725 Free PMC article. Review.
-
Erythropoietin: still on the neuroprotection road.Ther Adv Neurol Disord. 2012 May;5(3):161-73. doi: 10.1177/1756285611434926. Ther Adv Neurol Disord. 2012. PMID: 22590480 Free PMC article.
-
Application of Citicoline in Neurological Disorders: A Systematic Review.Nutrients. 2020 Oct 12;12(10):3113. doi: 10.3390/nu12103113. Nutrients. 2020. PMID: 33053828 Free PMC article.
-
Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome.Clin Interv Aging. 2012;7:113-8. doi: 10.2147/CIA.S29366. Epub 2012 May 10. Clin Interv Aging. 2012. PMID: 22654511 Free PMC article.
-
Citicoline: pharmacological and clinical review, 2022 update.Rev Neurol. 2022 Nov 30;75(s05):S1-S89. doi: 10.33588/rn.75s05.2022311. Rev Neurol. 2022. PMID: 36544369 Free PMC article. Review. English, Spanish.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical